Deep learning is a subdiscipline of artificial intelligence that uses a machine learning technique called artificial neural networks to extract patterns and make predictions from large data sets. The increasing adoption of deep learning across healthcare domains together with the availability of highly characterised cancer datasets has accelerated research into the utility of deep learning in the analysis of the complex biology of cancer. While early results are promising, this is a rapidly evolving field with new knowledge emerging in both cancer biology and deep learning. In this review, we provide an overview of emerging deep learning techniques and how they are being applied to oncology. We focus on the deep learning applications for omics data types, including genomic, methylation and transcriptomic data, as well as histopathology-based genomic inference, and provide perspectives on how the different data types can be integrated to develop decision support tools. We provide specific examples of how deep learning may be applied in cancer diagnosis, prognosis and treatment management. We also assess the current limitations and challenges for the application of deep learning in precision oncology, including the lack of phenotypically rich data and the need for more explainable deep learning models. Finally, we conclude with a discussion of how current obstacles can be overcome to enable future clinical utilisation of deep learning.
International challenges have become the standard for validation of biomedical image analysis methods. Given their scientific impact, it is surprising that a critical analysis of common practices related to the organization of challenges has not yet been performed. In this paper, we present a comprehensive analysis of biomedical image analysis challenges conducted up to now. We demonstrate the importance of challenges and show that the lack of quality control has critical consequences. First, reproducibility and interpretation of the results is often hampered as only a fraction of relevant information is typically provided. Second, the rank of an algorithm is generally not robust to a number of variables such as the test data used for validation, the ranking scheme applied and the observers that make the reference annotations. To overcome these problems, we recommend best practice guidelines and define open research questions to be addressed in the future.
Diabetes mellitus is a chronic disease and a major public health challenge worldwide. According to the International Diabetes Federation, there are currently 246 million diabetic people worldwide, and this number is expected to rise to 380 million by 2025. Furthermore, 3.8 million deaths are attributable to diabetes complications each year. It has been shown that 80% of type 2 diabetes complications can be prevented or delayed by early identification of people at risk. In this context, several data mining and machine learning methods have been used for the diagnosis, prognosis, and management of diabetes. In this paper, we propose utilizing support vector machines (SVMs) for the diagnosis of diabetes. In particular, we use an additional explanation module, which turns the “black box” model of an SVM into an intelligible representation of the SVM's diagnostic (classification) decision. Results on a real-life diabetes dataset show that intelligible SVMs provide a promising tool for the prediction of diabetes, where a comprehensible ruleset have been generated, with prediction accuracy of 94%, sensitivity of 93%, and specificity of 94%. Furthermore, the extracted rules are medically sound and agree with the outcome of relevant medical studies.